Welcome to our dedicated page for Swk Hldgs SEC filings (Ticker: SWKH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SWK Holdings Corporation (SWKH) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a life science focused specialty finance company with listed common stock and 9.00% Senior Notes due 2027 (SWKHL) on Nasdaq, SWK uses these filings to report its financial condition, portfolio activity, and material corporate events.
Investors can review Form 8-K filings in which SWK furnishes earnings press releases, investor presentations, and details on significant transactions. Recent 8-Ks include disclosures about quarterly financial results, non-GAAP reconciliations, monetization of royalty portfolios, special dividends, and the Agreement and Plan of Merger with Runway Growth Finance Corp. Other periodic reports, such as annual and quarterly filings, provide segment information for the Finance Receivables and Pharmaceutical Development Services businesses, along with discussions of non-GAAP measures like adjusted net income and non-GAAP tangible finance book value per share.
This page also helps users monitor information related to capital structure and securities, including the company’s common stock and its 9.00% Senior Notes due 2027. Filings may describe terms of these securities, risk factors, and updates on portfolio valuations and credit performance.
Stock Titan enhances access to SWKH filings with AI-powered summaries that explain complex sections in plain language, highlight key changes from prior periods, and surface items such as portfolio gains and losses, nonaccrual assets, and merger-related provisions. Real-time updates from EDGAR mean new SWK filings appear promptly, while Form 4 and other ownership reports can be used to track insider and major holder activity where available. This combination of raw documents and AI-generated insights allows investors, analysts, and researchers to review SWK’s regulatory history and understand how its specialty finance and pharmaceutical development activities are reflected in its official disclosures.
SWK Holdings Corporation entered into a merger agreement to be acquired through a multi-step merger by Runway Growth Finance Corp., ultimately becoming a wholly owned subsidiary of Runway. At closing, each SWK share (other than cancelled shares) will receive either cash based on SWK’s per-share net asset value or Runway common stock determined by a NAV-based exchange ratio, plus an additional Per Share Guaranteed Cash Payment expected to be approximately $0.74 per share, paid by Runway Growth Capital LLC.
SWK stockholders can elect cash or stock, subject to overall cash and stock limits that may cause pro rata reallocation between options. Unvested restricted stock will fully vest and convert into the same per-share merger consideration, subject to withholding. Closing is subject to customary conditions, including SWK stockholder approval, regulatory clearances and effectiveness of a Form N-14. A key stockholder holding about 69.9% of SWK’s voting power has agreed to vote in favor of the deal, and SWK may owe Runway an $8,225,000 termination fee if it accepts a superior proposal or changes its recommendation in specified circumstances.
SWK Holdings Corporation disclosed that it has entered into a definitive merger agreement with Runway Growth Finance Corp.. The transaction is structured as a series of mergers in which an indirect Runway subsidiary will merge with SWK, followed by additional merger steps, ultimately leaving SWK as part of a surviving entity that will be a wholly owned subsidiary of Runway.
The deal is subject to approval by SWK stockholders and other closing conditions, and the parties have issued a joint press release describing the transaction. The companies highlight numerous risks, including the possibility the mergers are not completed, uncertainty around expected synergies and cost savings, potential competing offers, stockholder litigation, and future regulatory or business changes. A joint registration statement on Form N-14 and proxy materials will be filed with the SEC to provide more details to stockholders.
SWK Holdings Corporation announced the full repayment of its loan to Elutia, receiving a $27.8 million payoff that exceeds the company’s net GAAP carrying value of $23.9 million as of June 30, 2025. The repayment follows Elutia’s sale of its BioEnvelope business to Boston Scientific for $88.0 million in cash. SWK expects to recognize approximately $1.4 million of incremental income from acceleration of exit fee recognition and approximately $1.4 million from the release of loan loss reserves, reflecting a net benefit to the company’s reported results from this transaction.
SWK Holdings Corporation filed a current report to furnish its press release and investor presentation covering 2025 second quarter financial results. The press release is attached as Exhibit 99.1 and the investor presentation as Exhibit 99.2.
The investor presentation includes financial information that uses Non-GAAP financial measures, along with reconciliations to the most comparable GAAP measures, in line with Regulation G. The company states that these Non-GAAP metrics are intended to give investors additional ways to view its operations and assess shareholder value, when considered together with GAAP results.
The information in this report, including the exhibits, is being furnished under Regulation FD and is not deemed “filed” or subject to liability under Section 18 of the Exchange Act unless specifically stated otherwise or incorporated by reference in another filing.
SWK Holdings Corporation (SWKH) reported interim financials focused on two segments: specialty finance (Finance Receivables) and Pharmaceutical Development (MOD3). As of June 30, 2025, the company held $237.6 million of net finance receivables and $8.0 million in cash, up from $5.9 million at year-end 2024. During the period the company sold a royalty portfolio for approximately $34.0 million, recording a $3.7 million lower-of-cost-or-market loss. The Board declared a $4.00 per share special cash dividend payable May 8, 2025. The company maintains a revolving credit facility (initially $45.0 million, commitments increased to $60.0 million) and $30.0 million of 9.00% senior notes due 2027. Assets and liabilities of the MOD3 CDMO business are classified as held for sale pending Aptar’s option exercise, aligning the company toward the specialty finance strategy. Unfunded commitments totaled $7.5 million.
SWK Holdings Corp director Robert K. Hatcher acquired 3,858 shares of common stock at $14.26 per share on June 16, 2025, increasing his direct holdings to 16,662 shares.
Key transaction details:
- The shares were issued as part of director compensation, with Hatcher electing to receive stock instead of cash payment
- The restricted shares have a vesting schedule, maturing on the earlier of June 16, 2026, or the next Annual Meeting of Stockholders
- Vesting is contingent on Hatcher's continued service as director
- The transaction was reported within the required filing window on June 18, 2025
This insider transaction demonstrates director alignment with shareholder interests through equity-based compensation, with Hatcher voluntarily choosing stock over cash payment for his board service.
Director Jerry Albright of SWK Holdings (SWKH) acquired 3,858 shares of common stock on June 16, 2025, at a price of $14.26 per share. Following this transaction, Albright's direct ownership increased to 10,832 shares.
Key transaction details:
- The shares were issued as part of director compensation, with Albright electing to receive stock instead of cash payment
- The restricted shares are subject to a vesting schedule, maturing on the earlier of:
- June 16, 2026
- The next Annual Meeting of Stockholders
- Vesting is contingent on Albright's continued service as director
This insider transaction demonstrates director alignment with shareholder interests through equity-based compensation.